EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Quince Therapeutics's Enterprise Value is $-21.92 Mil.
Quince Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-23.12 Mil. Therefore, Quince Therapeutics's EV-to-FCF for today is 0.95.
The historical rank and industry rank for Quince Therapeutics's EV-to-FCF or its related term are showing as below:
QNCX'
s EV-to-FCF Range Over the Past 10 Years
Min: -48.35 Med: 0 Max: 2.69
Current: 0.95
During the past 7 years, the highest EV-to-FCF of Quince Therapeutics was 2.69. The lowest was -48.35. And the median was 0.00.
QNCX's EV-to-FCF is ranked better than 62.96% of 378
companies
in the Biotechnology industry
Industry Median: 7.545
vs QNCX: 0.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Quince Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Quince Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Quince Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quince Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Quince Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Quince Therapeutics's EV-to-FCF falls into.
Quince Therapeutics's current Enterprise Value is $-21.92 Mil.
Quince Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Quince Therapeutics's PE Ratio for today is calculated as:
Quince Therapeutics's share price for today is $0.908.
Quince Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.760.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Quince Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Quince Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Quince Therapeutics (Quince Therapeutics) Business Description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QNCX has been successfully added to your 